Study S000135

Investigation of Safety and Efficacy of Five Doses of Semaglutide Versus Placebo and Open-label Liraglutide, as Add on Therapy, in Subjects Diagnosed With Type 2 Diabetes Currently Treated With Metformin or Controlled With Diet and Exercise A 12 Week Multi-centre, Multi National, Double-blind, Placebo-controlled, Randomised, Nine Armed Parallel Group, Dose Finding Trial

ClinicalTrials.gov record

Registration

Registration: NCT00696657
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 415
Start: 2008-06-03
Primary completion: 2009-02-05
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:semaglutide; DRUG:placebo; DRUG:liraglutide
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2007-003956-12

Registered primary outcomes

HbA1c [After 12 weeks of treatment.]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023489	Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease: Liraglutide and Diabetic Kidney Disease. Cherney DZ, Clinical journal of the American Society of Nephrology : CJASN	2020	Randomized trial	PMID 32149722 DOI	cites ClinicalTrials.gov:NCT00696657
R0013657	A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Nauck MA, Diabetes care	2016	Randomized trial	PMID 26358288 DOI	cites ClinicalTrials.gov:NCT00696657; registry reference DERIVED:26358288